SCHEMBL1716737

SCHEMBL1716737

CCC(CC)[C@@H](CO)NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 0.49
CA2 P00918 6/20 0.49
CA12 O43570 3/20 0.49
CA9 Q16790 3/20 0.49
CA14 Q9ULX7 3/20 0.49
CA1 P00915 5/20 0.46
MMP1 P03956 3/20 0.46
MMP9 P14780 3/20 0.46
MMP13 P45452 3/20 0.46
MMP8 P22894 3/20 0.46
CA3 P07451 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46
CA13 Q8N1Q1 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
MMP3 P08254 2/20 0.46
MMP7 P09237 2/20 0.46
ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1716735 1.00 MMP2 (0.49) MMP2CA2CA12CA9CA14
SCHEMBL3202961 0.92 S1PR1 (0.46) MMP2CA2CA12CA9CA14
SCHEMBL3179877 0.90 MMP2 (0.44) MMP2CA2CA12CA9CA14
SCHEMBL3186528 0.88 MMP2 (0.42) MMP2CA2CA12CA9CA14
SCHEMBL13750129 0.87 MMP2 (0.41) MMP2CA2CA12CA9CA14
SCHEMBL3178129 0.87 MMP2 (0.41) MMP2CA2CA12CA9CA14
SCHEMBL3186653 0.87 MMP2 (0.41) MMP2CA2CA12CA9CA14
SCHEMBL3198456 0.87 CA2 (0.56) MMP2CA2CA12CA9CA14
SCHEMBL13335267 0.87 CA2 (0.56) MMP2CA2CA12CA9CA14
SCHEMBL3177359 0.87 CA2 (0.56) MMP2CA2CA12CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE HOTH THERAPEUTICS, INC. 2025-01-30 US claimed
EP-1549306-A4 SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION WYETH CORP (US) 2007-06-06 EP claimed
US-20070037778-A1 Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide WYETH (US) 2007-02-15 US claimed
US-7166622-B2 Substituted phenylsulfonamide inhibitors of beta amyloid production WYETH (US) 2007-01-23 US claimed
EP-1549306-A1 SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION Wyeth (US) 2005-07-06 EP claimed
US-20040006050-A1 Substituted phenylsulfonamide inhibitors of beta amyloid production WYETH (US) 2004-01-08 US claimed
WO-2003103660-A1 SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION WYETH (US) 2003-12-18 WO claimed
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS KARUNA THERAPEUTICS INC (US) 2026-02-26 US disclosed
EP-4634193-A1 SUBSTITUTED DIHYDROPYRROLO[3, 4-D]PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2025-10-22 EP disclosed
EP-4634194-A1 SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2025-10-22 EP disclosed
US-12421242-B2 Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions Karuna Therapeutics, Inc. (US) 2025-09-23 US disclosed
US-12398119-B2 Piperazine azaspiro derivatives PFIZER INC. (US) 2025-08-26 US disclosed
WO-2025043067-A2 PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS FOR THE TREATMENT OF CHRONIC HEART FAILURE CARDURION PHARMACEUTICALS, INC. (US) 2025-02-27 WO disclosed
US-20090030003-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC 2009-01-29 US disclosed
EP-1549306-A4 SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION WYETH CORP (US) 2007-06-06 EP disclosed
US-20070037778-A1 Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide WYETH (US) 2007-02-15 US disclosed
US-7166622-B2 Substituted phenylsulfonamide inhibitors of beta amyloid production WYETH (US) 2007-01-23 US disclosed
EP-1549306-A1 SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION Wyeth (US) 2005-07-06 EP disclosed
US-20040006050-A1 Substituted phenylsulfonamide inhibitors of beta amyloid production WYETH (US) 2004-01-08 US disclosed
WO-2003103660-A1 SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION WYETH (US) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398119-B2 Piperazine azaspiro derivatives CHRM1, CHRM2, CHRM5 MMP2 3730/4885CA2 3234/4885CA12 4175/4885
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE TACR1, ACHE, TACR2 MMP2 1404/4885CA2 1131/4885CA12 1083/4885
US-20090030003-A1 AMINO-HETEROCYCLIC COMPOUNDS PDE9A, PDE2A, PDE10A MMP2 1140/4885CA2 3251/4885CA12 4295/4885
US-20070037778-A1 Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide BACE1, APP, PSEN1 MMP2 3545/4885CA2 3464/4885CA12 4418/4885
US-12421242-B2 Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions CHRM3, CHRM4, CHRM2 MMP2 3593/4885CA2 2473/4885CA12 3609/4885
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS CHRM3, CHRM2, CHRM1 MMP2 4216/4885CA2 355/4885CA12 2117/4885
US-20040006050-A1 Substituted phenylsulfonamide inhibitors of beta amyloid production APP, BACE1, PSEN1 MMP2 2539/4885CA2 2822/4885CA12 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.